CME Symposium

IN ASSOCIATION WITH THE

21st

WCIRDC

Breaking New Ground in Heart Failure Treatment

Friday December 8, 2023
6:15pm – 7:30pm PST
Hilton Universal City Hotel
Los Angeles, California

This is a CME Symposium Supported by an Educational Grant from Lexicon Pharmaceutical
Free for all 21st WCIRDC Attendees | Register Online: wcir.org/registration
All Content available ON DEMAND for ONE YEAR following the meeting

Provided By:  
Administered By:
6:15 pm – 7:30 pm Dinner CME Symposium

**Breaking New Ground in Heart Failure Treatment**
Chairs: Matthew Budoff, MD • Yehuda Handelsman, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 pm</td>
<td>Introduction &amp; Pre CME Questions</td>
<td>Yehuda Handelsman, MD</td>
</tr>
<tr>
<td>6:25 pm</td>
<td>Prevalence, Pathophysiology and Morbidities of Heart Failure</td>
<td>Matthew J. Budoff, MD</td>
</tr>
<tr>
<td>6:40 pm</td>
<td>Contemporary Approach to Management of Heart Failure</td>
<td>Stephen J. Greene, MD</td>
</tr>
<tr>
<td>6:55 pm</td>
<td>Sotagliflozin: The Next Generation of Heart Failure Management</td>
<td>Darren McGuire, MD, MHSc</td>
</tr>
<tr>
<td>7:10 pm</td>
<td>Panel Discussion, Q&amp;A, and Post-CME: Advancing the Care of Heart Failure- Relationship to CKD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel:</td>
<td>Matthew J. Budoff, MD, Stephen J. Greene, MD, Darren McGuire, MD, MHSc, Matthew R. Weir, MD</td>
</tr>
<tr>
<td></td>
<td>Moderator:</td>
<td>Yehuda Handelsman, MD</td>
</tr>
<tr>
<td>7:25 pm</td>
<td>Post-CME Questions &amp; Concluding Remarks</td>
<td></td>
</tr>
<tr>
<td>7:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Program Description**

This CME satellite symposium will explore the changing landscape of therapies for patients with HF with or without diabetes. The program will address the gaps in physicians’ knowledge of the Epidemiology & and pathophysiology of heart failure, the new 2022 ACC/AHA/HFSA Ejection Fraction based Heart Failure management guidelines, and the emerging role of sotagliflozin an SGLT2/1- in heart Failure patients with and without T2D, CKD and other CV risks.

**Learning Objectives**

Upon completion of this CME symposium, participants should be able to:

- Discuss the epidemiology of HF
- Understand the Pathophysiology of HF
- Be Aware of the Ejection Fraction based 2022 treatment Guidelines for HF
- Describe the Potential Mode of action of SGLT2 & SGLT1 inhibitors.
- Develop management strategies for patients with HF including those with DM & CKD

**Target Audience**

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
This CME Program Supported by an Educational Grant from

Lexicon Pharmaceuticals